Speculative approaches in hypertension: concepts and drugs of the future. Fed Proc 1981 Jun;40(8):2291-5
Date
06/01/1981Pubmed ID
6263717Scopus ID
2-s2.0-0019420710 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Despite the availability and application of more effective antihypertensive drugs over the past 3 decades, hypertension continues to be a major risk factor for the development of premature cardiovascular disease. Moreover, failure to elucidate the pathogenesis of essential hypertension, noncompliance, and difficulties in defining the appropriate level of blood pressure elevation requiring therapy, continue to mitigate against the adequate control of hypertension. Some of these problems may be overcome by the availability of depot forms of antihypertensive medication or implantable drug delivery systems, or by the use of several recently developed antihypertensive drugs. These include dopaminergic agonists, selective alpha-adrenergic agents, calcium antagonists, medullary neutral lipids, gamma-aminobutyric acid agonists, and inhibitors of renin or phenethylamine N-methyl-transferase. In addition, the potential involvement of morphinomimetic peptides, prostaglandins, tonin, and bradykinin in blood pressure control or certain hypertensive states suggests that drugs developed to block or potentiate the actions of these substances may have important therapeutic applications.
Author List
Graham RM, Campbell WBAuthor
William B. Campbell PhD Professor in the Pharmacology and Toxicology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntihypertensive Agents
Bromocriptine
Dopamine
Forecasting
Humans
Hypertension
Mineralocorticoids
Peptides
Prostaglandins
Receptors, Adrenergic, alpha
Renin
Research